Invivoscribe Receives Regulatory Approval for FLT3 Mutation Assay in Japan

Sep 27, 2018

|

NEW YORK (GenomeWeb) – Invivoscribe announced today that it has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA)for its LeukoStrat CDx FLT3 Mutation Assay companion diagnostic.

The firm expects to begin shipments of the FTL3 assay from LabPMM GK, the assay's marketing authorization holder in Japan, in late 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Invivoscribe Receives Regulatory Approval for FLT3 Mutation Assay in Japan

To read the full story....

Breaking News

Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

LabCorp, Genfit Partner to Commercialize Liver Disease Diagnostic Test

Hologic Receives FDA Emergency Use Authorization for SARS-CoV-2 Testing of Asymptomatic Individuals

Quotient Limited Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

What's Popular?

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

Quotient Limited Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

LabCorp, Genfit Partner to Commercialize Liver Disease Diagnostic Test

Sponsorships